Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stargardt Disease: early-phase trial registry
14 of 17 indexed Stargardt Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 14 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Stargardt Disease: 17 US clinical trials tracked, 14 recruiting.
Stargardt Disease is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Nanoscope Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition stargardt-disease
OPEN 14 | RECR 82% | LATE 0 | EARLY 9 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Cardiogenic Shock (82% recruiting · 17 trials)
Stargardt Disease lists 14 open slots (82% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stargardt Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stargardt Disease is recruiting above its size-band peers.
14 of 17 indexed trials (82.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Stargardt Disease trials is spread across many organizations.
Nanoscope Therapeutics accounts for 2 of 17 trials (11.8%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Stargardt Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 17 trials that report a genuine target (sentinel values excluded). 14 of those (82.4%) plan for fewer than 100 participants.
-
Stargardt Disease splits between interventional and observational designs.
10 interventional and 7 observational studies make up this index (58.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Stem Cell Ophthalmology Treatment Study II
MD Stem Cells
NCT03011541
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Ray Therapeutics
NCT06375239
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Astellas Pharma Global Development
NCT07425574
An Observational Study in Children and Adults With Stargardt Disease
AAVantgarde Bio Srl
NCT06591806
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Splice Bio
NCT06435000
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
AAVantgarde Bio Srl
NCT07161544
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
Splice Bio
NCT06942572
Oral Metformin for Treatment of ABCA4 Retinopathy
National Eye Institute (NEI)
NCT04545736
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
Ocugen
NCT05956626
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
Ascidian Therapeutics
NCT06445322
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Nanoscope Therapeutics
NCT06805474
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
Ray Therapeutics
NCT07439887
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
University of Rochester
NCT06319872
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Ascidian Therapeutics
NCT06467344
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Alkeus Pharmaceuticals
NCT04239625
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Nanoscope Therapeutics
NCT06048185
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Kubota Vision
NCT03033108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Stargardt Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stargardt Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stargardt Disease page
17 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Stargardt Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nanoscope Therapeutics sponsors the most Stargardt Disease trials on record, review their full trial history before evaluating a specific study. See Nanoscope Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stargardt Disease condition card totals 17 registered trials; most-linked intervention Emixustat; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.